Clinical trials: cp
Intestinal Permability
CP: Intestinal Permeability
The goal of this clinical trial is to evaluate the effects of 45 days daily administration of three different doses (2.5g, 5g, and 10g) of collagen peptide in healthy adults as compared to a Placebo on intestinal permeability…
- Trial name
- NCT07586930
- Testing
- AP GUT collagen peptides
- Where
- Ireland
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia…
- Trial name
- ASC4INDIA (NCT06427811)
- Testing
- Asciminib
- Where
- 10 sites in India
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients.
- Trial name
- ENESTop (NCT01698905)
- Testing
- nilotinib
- Where
- 62 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Primary Objective for this study is to evaluate changes in chronic low grade non-hematological adverse events experienced by patients who have been treated with at least 6 months of imatinib and who have not responded to…
- Trial name
- MACS1532 (NCT02115386)
- Testing
- Nilotinib
- Where
- Russia
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients are switched from imatinib to…
- Trial name
- MACS0999 (NCT00980018)
- Testing
- Nilotinib
- Where
- 23 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Chronic Myelogenous
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of asciminib versus best available therapy in Chinese patients with Chronic Myelogenous Leukemia in chronic phase…
- Trial name
- NCT04795427
- Testing
- asciminib, best available treatment
- Where
- 20 sites in China
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Castration-Resistant Prostate Cancer (CRPC)
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT07683013
- Testing
- CP-PCA07, Enzalutamide 40 mg capsule
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON…
- Trial name
- NCT06750419
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 8 sites in China
- Volunteers
- 82 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Chronic Myeloid Leukemia in Chronic Phase
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre…
- Trial name
- ASC4CN (NCT07375355)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase…
- Conditions
- CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
- Trial name
- NCT03578367
- Testing
- Asciminib add-on, Imatinib, Nilotinib
- Where
- 30 sites in United States, Austria and 13 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Cerebral Palsy (CP)
Double-blind Comparative Randomized Multicenter
The name of the study: is a double-blind comparative randomized trial to evaluate the safety and efficacy of the drug Miotox® with the participation of children with cerebral palsy The code/number of the Protocol No.
- Trial name
- NCT06840158
- Testing
- Miotox (Botulinum toxin type A is a hemagglutinin complex), BOTOX®
- Where
- 3 sites in Russia
- Volunteers
- 80 people
- Sponsor
- Innopharm LLC
Lower Limb Ulcers
VergenixTM Flowable Gel in Patients With Lower Limb Ulcers
Vergenix Flowable Gel is indicated for the management of acute and chronic wounds
- Trial name
- CP-FG-001 (NCT02598180)
- Testing
- VergenixTM Flowable Gel
- Where
- 4 sites in Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Collplant
Congenital Cytomegalovirus Infection
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest (BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV infection.
- Trial name
- PreCyssion (NCT05170269)
- Testing
- BT097
- Where
- 5 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Biotest
STEMI
Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction - Safety and Feasibility Study
Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasible
- Trial name
- DTU (NCT03000270)
- Testing
- Impella unloading prior to PPCI
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abiomed Inc.
Chronic Myelogenous Leukemia in Chronic Phase
RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
This is a non-interventional, prospective, observational single arm study describing the real-world effectiveness, tolerability, adherence, Healthcare Resource Utilization (HCRU) and Patient-Reported Outcome (PRO) data of…
- Trial name
- ASC4REAL (NCT06684964)
- Testing
- asciminib
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
CML, Chronic Phase, CML, Accelerated Phase
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation.
- Trial name
- NCT05367700
- Testing
- HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion)
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5
- Trial name
- ENESTgoal (NCT01744665)
- Testing
- nilotinib
- Where
- 54 sites in United States
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
- Trial name
- NCT01394666
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia - Chronic Phase
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior…
- Trial name
- AIM4CML (NCT04666259)
- Testing
- ABL001
- Where
- 26 sites in United States
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal…
- Trial name
- MACS0911 (NCT01043874)
- Testing
- Nilotinib
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals